Neuroprotection

Hydroxytyrosol acetate
Catalog No: CFN90927

Hydroxytyrosol acetate has antibacterial, neuroprotective , antioxidant and anti-inflammatory effects, it can enhance the fluorescent intensity of DNA binding molecules and mediated supercoiled DNA relaxation. Hydroxytyrosol acetate can improve the oxidative events and return pro-inflammatory proteins expression to basal levels probably through JAK/STAT, MAPKs and NF-κB pathways. Hydroxytyrosol acetate and polyphenols hydroxytyrosol administered orally can inhibit platelet aggregation in rats and that a decrease in thromboxane synthesis along with an increase in nitric oxide production contributed to this effect.

Dehydroevodiamine
Catalog No: CFN90944

Dehydroevodiamine has anticholinesterase activity and an anti-amnesic effect, it also may be a novel and effective ligand for improvement of beta-amyloid type amnesia. Dehydroevodiamine has antiarrhythmic, and anti-inflammatory properties, the effect of dehydroevodiamine-mediated inhibition of the expression LPS-induced iNOS and COX-2 genes is due to under the suppression of NF-kappaB activation in the transcriptional level.

Notoginsenoside Fa
Catalog No: CFN93284

Notoginsenosides Fa and R4 show significant neurite outgrowth enhancing activities in human neuroblastoma SK-N-SH cells.

Incensole acetate
Catalog No: CFN93207

Incensole acetate is a novel anti-inflammatory compound that inhibits NF-κB activation. Incensole acetate has protective effects on cerebral ischemic injury, it can reduce depressive-like behavior and modulate hippocampal BDNF and CRF expression of submissive animals.

2,5-Dihydroxyacetophenone
Catalog No: CFN93182

2,5-Dihydroxyacetophenone is an uncompetitive inhibitor of murine tyrosinase (K(I) 0.28mm), it strongly inhibits both melanogenesis and cellular tyrosinase activity, it possesses anti-inflammatoryanti-anxiety, and neuroprotective qualities. 2,5-Dihydroxyacetophenone treatment can induce a sustained activation of JNK, ERK1/2, and p38 MAPKs, it also can potentiate the pro-apoptotic and anti-proliferative effects of bortezomib in U266 cells.